Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of June 2018, specifically dated June 11, 2018. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a vehicle to incorporate a press release regarding clinical developments rather than to report financial results.
Material Changes
The primary material change reported is the announcement of new pre-clinical developments concerning the company's drug candidate, Namodenoson, which is being developed for the treatment of Non-Alcoholic Steatohepatitis (NASH).
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" section of the attached press release (Exhibit 99.1). No specific financial guidance or quantitative outlook is provided within the text of this Form 6-K. The document notes that the press release is incorporated into the company's Registration Statements on Form F-3.
Investor Verification Checklist
- Review the full text of the press release dated June 11, 2018 (Exhibit 99.1) for specific details on the Namodenoson pre-clinical data.
- Verify the "Forward Looking Statements" included in the press release for potential risks and assumptions.
- Check subsequent filings for any updates on the NASH drug development timeline or financial impact of these developments.